Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $30

Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc.

AMLX

0.00

Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ: AMLX) with a Buy and raises the price target from $25 to $30.